Hemab Therapeutics Holdings, Inc. Common Stock · COAG

Exhibit 99.1 Hemab Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update Dosed first participant in Phase 1 clinical trial of HMB-003 for management of heavy menstrual bleeding, a condition affecting more than 23 million women in the U.S. alone Announced data showing HMB-003 reduced severe menstrual bleeding in a cynomolgus monkey model; data to be presented at the 68th ASH Annual Meeting and Exposition in December 2026 Announced first clinical data for s…

8-K · 2026-11-10 · 0001193125-26-454414

EX-99.1 2 d180684dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Hemab Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update Multiple scientific data presentations, including five oral presentations across three programs, at the International Society on Thrombosis and Haemostasis (ISTH) 2026 Congress in Paris, France New clinical data on HMB-002 demonstrated ≥ 2.4-fold increase in Von Willebrand Factor (VWF) and Factor VIII (FVIII), stronger than anticipated pr…

8-K · 2026-08-11 · 0001193125-26-343421

EX-99.1 2 d102408dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Hemab Therapeutics Reports First Quarter 2026 Financial Results Completed Initial Public Offering in May 2026, raising gross proceeds of $346.7 million and listing on Nasdaq Granted Breakthrough Therapy Designation for sutacimig in Glanzmann thrombasthenia CAMBRIDGE, MA, USA & COPENHAGEN, Denmark - May 21 2026 - Hemab Therapeutics Holdings, Inc., a clinical-stage biotechnology company developing therapies that reimagine the treatm…

8-K · 2026-05-21 · 0001193125-26-233375

EX-4.2 5 d50309dex42.htm EX-4.2 EX-4.2 Exhibit 4.2 WARRANTAFTALE WARRANT AGREEMENT Dato/Date: The English part of this document is an unofficial translation of the Danish text. In the event of disputes or misunderstandings arising from the translation, the Danish text shall prevail. WARRANTAFTALE WARRANT AGREEMENT INDGÅET MELLEM BETWEEN Hemab ApS Hemab ApS (CVR-nr. 40837590) (CBR-no. 40837590) (“Selskabet”) …

S-1 · 2026-04-10 · 0001193125-26-151378

EX-4.3 6 d50309dex43.htm EX-4.3 EX-4.3 Exhibit 4.3 INVESTORS’ RIGHTS AGREEMENT This INVESTORS’ RIGHTS AGREEMENT (this “Agreement”) is made as of March 30, 2026, by and among Hemab Therapeutics Holdings, Inc., a Delaware corporation (the “Company”), the Investors (as defined below) and the Key Holders (as defined below). RECITALS WHEREAS, the Company, the Investors and the Key Holders are parties to that certain Share Contribution and Exchange Agreement of even date herewith by and among…

S-1 · 2026-04-10 · 0001193125-26-151378